These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 136805)
61. The role of oral anticoagulants in tumor biology. Weitz IC; Liebman HA Semin Thromb Hemost; 2007 Oct; 33(7):695-8. PubMed ID: 18000797 [TBL] [Abstract][Full Text] [Related]
62. [Advantages and hazards of drug treatment in surgery. Anticoagulants and fibrinolytic agents]. Gross R Chirurg; 1968 May; 39(5):201-8. PubMed ID: 4974339 [No Abstract] [Full Text] [Related]
64. The use of heparin for treating human malignancies. Ornstein DL; Zacharski LR Haemostasis; 1999 Dec; 29 Suppl S1():48-60. PubMed ID: 10629404 [TBL] [Abstract][Full Text] [Related]
66. Anticoagulant therapy. Hellett S Nurs Stand; 2011 Aug 24-30; 25(51):59. PubMed ID: 21922744 [No Abstract] [Full Text] [Related]
67. Fibrinolysis. V. The thrombolytic and anticoagulant activity of mold fibrinolysin (Aspergillin O) in vivo. MARIN HM; STEFANINI M; SOARDI F; MUELLER L J Lab Clin Med; 1961 Jul; 58():47-59. PubMed ID: 13766766 [No Abstract] [Full Text] [Related]
68. Initial tumor cell arrest in animals of defined coagulative status. Glaves D; Weiss L Int J Cancer; 1978 Jun; 21(6):741-6. PubMed ID: 580932 [TBL] [Abstract][Full Text] [Related]
69. Rationale and experimental design for the VA Cooperative Study of Anticoagulation (Warfarin) in the Treatment of Cancer. Zacharski LR; Henderson WG; Rickles FR; Forman WB; Cornell CJ; Forcier RJ; Harrower HW; Johnson RO Cancer; 1979 Aug; 44(2):732-41. PubMed ID: 383261 [TBL] [Abstract][Full Text] [Related]
70. Inhibition of metastases by anticoagulants. Hejna M; Raderer M; Zielinski CC J Natl Cancer Inst; 1999 Jan; 91(1):22-36. PubMed ID: 9890167 [TBL] [Abstract][Full Text] [Related]
71. Anticoagulant treatment of rats with Walker 256 carcinosarcoma. Owen CA J Cancer Res Clin Oncol; 1982; 104(1-2):191-3. PubMed ID: 7130245 [TBL] [Abstract][Full Text] [Related]
72. Letter: Anticoagulant control, immunosuppression, and glomerulonephritis. Barkhan P; Black PJ; Thomas T; Brown CB; Cameron JS; Ogg CS Lancet; 1975 Jan; 1(7897):36. PubMed ID: 46350 [No Abstract] [Full Text] [Related]
73. [ON SOME CONCLUSIONS IN THE EXPERIMENTAL AND CLINICAL STUDY OF FIBRINOLYSIS]. ANDREENKO GV Ter Arkh; 1963 Jul; 35():3-12. PubMed ID: 14077561 [No Abstract] [Full Text] [Related]
74. EXPERIMENTAL STUDIES OF THE INTRAVASCULAR DISSEMINATION OF ASCITIC V2 CARCINOMA CELLS IN THE RABBIT, WITH SPECIAL REFERENCE TO FIBRINOGEN AND FIBRINOLYTIC AGENTS. WOODS JR Bull Schweiz Akad Med Wiss; 1964 May; 20():92-121. PubMed ID: 14145390 [No Abstract] [Full Text] [Related]
75. Surgical adjuvant therapy for potentially curable cancer: the rationale of adjuvant chemotherapy and anticoagulant therapy. Gray BN Aust N Z J Surg; 1977 Oct; 47(5):576-80. PubMed ID: 273400 [No Abstract] [Full Text] [Related]
76. The protease consortium: an alliance to advance the understanding of proteolytic enzymes as therapeutic targets for cancer. Giranda VL; Matrisian LM Mol Carcinog; 1999 Nov; 26(3):139-42. PubMed ID: 10559787 [No Abstract] [Full Text] [Related]
77. [Terrilitin in treatment of experimental hyphema]. Logaĭ IM Oftalmol Zh; 1975; 30(5):362-3. PubMed ID: 130588 [No Abstract] [Full Text] [Related]
78. [Immobilized enzymes and the prospects for their use in otolaryngology (a review)]. Veremeenko KN; Karpenko GF Zh Ushn Nos Gorl Bolezn; 1979; (6):72-6. PubMed ID: 390919 [No Abstract] [Full Text] [Related]
79. Prophylaxis of metastases formation by unspecific immunologic stimulation associated with heparintherapy. Kiricuta I; Todorutiu C; Muresian T; Risca R Cancer; 1973 Jun; 31(6):1392-6. PubMed ID: 4709954 [No Abstract] [Full Text] [Related]
80. Use of anticoagulant and fibrinolytic agents. MOSER KM Dis Mon; 1960 Mar; 1960():1-44. PubMed ID: 13848677 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]